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GermanyA B S T R A C TObjectives: Atrial ﬁbrillation (AF) is a factor in the development of
thrombi that can lead to ischemic strokes. Anticoagulants are crucial
in preventing strokes among patients with AF but are associated with
bleeding risks. Recent studies have shown that despite anticoagu-
lants’ efﬁcacy in stroke prevention, many patients with AF receive
subtherapeutic levels of anticoagulation because of concerns about
bleeding. Of particular interest is to quantify the perceived relative
importance of treatment-related beneﬁts and risks and how these
perceptions vary between patients and physicians in different coun-
tries. Methods: Patients’ and physicians’ preferences were elicited
using a discrete-choice experiment. We evaluated disagreements in
preferences for the beneﬁts and risks of anticoagulants. Results:
A total of 186 patients with AF and 107 physicians in the United States
completed the survey. In Japan, 152 patients and 164 physicians
completed the same survey. Japanese patients were relatively less
averse than US patients to bleeding risks. Physicians in both countries
did not distinguish between nondisabling and disabling strokes. USee front matter Copyright & 2015, International S
r Inc. This is an open access article under the CC
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apan.patients were less tolerant than physicians of nonmajor clinically
relevant bleeding risk when this risk was a consequence of preventing
nondisabling strokes. Japanese patients were generally more tolerant
than physicians of bleeding risks when the risks were consequences
of preventing both nondisabling and disabling strokes. Conclusions:
Overall, preferences for anticoagulant beneﬁts and risks were not
statistically different between patients and physicians in the United
States, nor were there differences in preferences for different stroke
risks between physicians in the United States and Japan; however,
preferences were different between patients and physicians in Japan.
Keywords: atrial ﬁbrillation, bleeding, conjoint-analysis, discrete-
choice experiment, preferences, stroke prevention.
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Atrial ﬁbrillation (AF) plays a central role in the development of
thrombi in the left atrium that can eventually migrate and block
blood ﬂow to the brain, leading to ischemic stroke [1]. Patients
with AF have a ﬁvefold increase in the risk of ischemic stroke
than do patients without AF, and strokes among these patients
are associated with more debilitating sequelae such as difﬁcultywalking, speaking, or swallowing, which require constant nursing
care and assistance [2–4]. Given the potentially devastating
impact of ischemic strokes among these patients, primary objec-
tives in the management of AF are ventricular rate control and
the prevention of arterial thrombi with anticoagulants [5–7].
Recent studies have shown that although anticoagulants have
greater efﬁcacy than alternative treatments for ischemic stroke
prevention, many patients who take anticoagulants receiveociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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mended intensity, for example, as measured by the target
international normalized ratio for warfarin, whereas others do
not receive anticoagulants even when anticoagulation is recom-
mended [8–11]. Subtherapeutic anticoagulation in patients with
AF is believed to be driven by perceptions of the impact of the
beneﬁts and risks of anticoagulants [8–9,12].
In Japan, the use of anticoagulants among patients with AF
was stable during the last decade, with approximately 50% of the
patients treated [13,14]. For the United States, the use of oral
anticoagulants among patients with AF has remained constant
around 60% since 2007 [15].
There is evidence that Japanese physicians maintain lower
international normalized ratio levels for treated patients with AF
than do US physicians [13]. One possible explanation for the
lower intensity of anticoagulation is concern about bleeding risks.
To explore this hypothesis, we sought to understand how the
relative importance of treatment-related beneﬁts and risks is
perceived and how the relative importance of beneﬁts and risks
varies between patients and physicians and between these
groups in the United States and Japan.Methods
Survey
Survey respondents were presented with a series of choice
questions, each asking them to select a preferred alternative
between a pair of hypothetical anticoagulant proﬁles deﬁned by
varying rates of treatment-induced rates of events. Each hypo-
thetical proﬁle was described by key events measured in clinical
trials of anticoagulants. Clinical experts were consulted to reﬁne
the list of events, review the event deﬁnitions, and determine theTable 1 – Events and event rates included in the
discrete-choice experiment questions.
Event* Event rates
Minor stroke (nondisabling stroke) 0% chance
1% chance
3% chance
Major stroke that results in permanent
disability (disabling stroke)
0% chance
1% chance
3% chance
Blood clot in the leg (non-CNS,
systemic embolism)
0% chance
2% chance
5% chance
Heart attack (myocardial infarction) 0% chance
4% chance
9% chance
Moderate bleeding (nonmajor
clinically relevant bleeding)
0% chance
14% chance
25% chance
Nonfatal major bleeding
(extracranial major bleeding)
0% chance
3% chance
8% chance
All-cause death 1% chance
3% chance
4% chance
6% chance
CNS, central nervous system.
* Apart from all-cause death, all events presented in this table are
nonfatal events.range of rates for each event. Table 1 presents the ﬁnal list of
events and rates included in the survey.
A patient survey and a physician survey were developed and
pretested using in-depth, semi-structured interviews with eight
patients and nine physicians in the United States. Both surveys
were reﬁned on the basis of pretest ﬁndings to ensure the clarity of
both event descriptions and choice questions in the discrete-choice
experiment surveys. Separate language-appropriate deﬁnitions
were provided for patients and physicians. The surveys were then
translated into Japanese, reviewed by three Japanese clinical
experts, and pretested using in-depth, semi-structured interviews
with two patients with AF and one physician in Japan [16,17].
Fig. 1 shows an example of a choice question presented to
patients. Each patient was asked to make a series of choices
between anticoagulants as if choosing for himself or herself,
while physicians chose treatments for four unique virtual
patients (Table 2). The four virtual patients are prototypical
patients that physicians who treat AF might encounter in clinical
practice. These patient descriptions frame the prescribing deci-
sion in the choice questions. Without these patient proﬁles,
physicians may not have enough information to decide which
treatment is most appropriate in their clinical judgment.
Because end points presented in Table 1 represent different
severities of a smaller set of events, the end points were grouped
into broad event categories (i.e., chance of stroke, chance of blood
clot, chance of heart attack, and chance of bleeding). To reduce
the complexity of the survey, only one end point in each of these
broad event categories was presented in each choice question.
Preferences for all-cause death were elicited in a follow-up
question that asked respondents to revisit their treatment
choices if their preferred option was associated with a nonzero
incidence of all-cause death. The pattern of choices was analyzed
to quantify the relative importance of each change in event rates
associated with the hypothetical anticoagulants.
Survey Sample
US patients were recruited from an online panel and were at least
18 years old and had a self-reported physician diagnosis of AF.
Primary care physicians, internists, and cardiologists who currently
treated patients with AF and were board-eligible or board-certiﬁed
in their specialty were recruited from an online panel of US
physicians. Japanese patients were required to be at least 45 years
old and have a self-reported physician diagnosis of AF. Japanese
physicians were required to be board-eligible or board-certiﬁed
cardiologists, internists, neurologists, or neurosurgeons who cur-
rently treated patients with AF. Recruitment of patients and
physicians is described elsewhere [16,17]. The online survey was
administered in the United States between November and Decem-
ber 2010 and in Japan between November 2011 and January 2012.
All survey instruments and administration protocols were
approved by RTI International’s Ofﬁce of Research Protection
and Ethics (Research Triangle Park, NC).
Study Analysis
All events in Table 1 were included as explanatory variables in a
random-parameters logit (RPL) model. In RPL models, the depend-
ent variable is the treatment choice and the explanatory variables
include the event incidence in the choice questions. The RPL model
assumes that differences in event incidence across treatments
determine the relative attractiveness of treatment options. Thus,
the likelihood of choice for a treatment can be linked to the relative
preference for that treatment and the contribution of each event
incidence to a relative preference measure can be inferred from the
contribution of the event incidence to treatment choice [18]. A
main-effects model was estimated using a polynomial
Fig. 1 – Example of a trade-off question in patient survey. All events presented in this ﬁgure are nonfatal events. CNS, central
nervous system.
Table 2 – Virtual patient proﬁles.
Proﬁle number Key characteristics
Proﬁle 1  71-y-old woman
 CHADS2 score ¼ 2
 No information on prior stroke
 No information on prior MI
 No prior bleeding
 Takes medication for hypertension and diabetes
 CrCl ¼ 65 ml/min
 Active
Proﬁle 2  80-y-old woman
 CHADS2 score ¼ 4
 Prior stroke
 No information on prior MI
 No information on prior bleeding
 Takes medication for hypertension and osteoarthritis
 Best blood pressure ¼ 160/70 mm Hg
 Fractured hip from fall
Proﬁle 3  76-y-old man
 CHADS2 score ¼ 3
 No prior stroke
 Prior MI and mild CHF
 No information on prior bleeding
 Takes medication for hypertension and hypercholesterolemia
 CrCl ¼ 40 ml/min
 Deteriorated renal function
Proﬁle 4  79-y-old man
 CHADS2 score ¼ 6
 Prior stroke
 No information on prior MI
 No information on prior bleeding
 Diabetes
 Takes medication for hypertension and CHF
 CrCl ¼ 30 ml/min
 Homebound
Note. CHADS2: Score estimating the risk of stroke in patients with AF. Higher score means higher risk [21,22].
AF, atrial ﬁbrillation; CHF, congestive heart failure; CrCl, creatinine clearance; MI, myocardial infarction.
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effect that each event incidence had on treatment preferences.
Speciﬁcation tests were conducted to identify the most parsimo-
nious speciﬁcation for each sample. Physician and patient data
were analyzed separately and by country.
Because the RPL models estimate the effect of event incidence
on the relative preference for treatments, they produce coefﬁ-
cient estimates (preference weights) that are interpreted as the
relative strength of preference for each event incidence. For each
event, we estimated a parameter (i.e., random parameter) char-
acterizing and controlling for the degree of heterogeneity in
preference weights across respondents. The variation in prefer-
ences for all events was assumed to follow a normal distribution.
Changes in preference weights induced by changes in event
incidences are considered measures of importance of an event
(importance weights) because they reﬂect how important is an
event in the decision to choose one treatment over another given
incidence differences. To facilitate the interpretation of the prefer-
ence results, the importance weights are calculated for a change in
the incidence of each event relative to the importance of a change
in the risk of all-cause death. Thus, the relative importance is the
ratio of the importance estimate for each event to the mean
importance estimate for all-cause death. Because these measures
of relative importance are constructed as a ratio of the preference
for each event and all-cause death, their magnitude across sub-
groups reﬂects how important all-cause death is relative to all other
events. The more important all-cause death was for respondents,
the smaller the magnitude of the importance of all other events. All
conﬁdence intervals around the relative importance weights were
estimated using a simulation method [19].Table 3 – Sample characteristics: Patients.
Characteristic Japan (N ¼ 15
Demographic
Mean age (y), mean  SD 63.3  9.05
Sex: female 18 (11.8)
College degree or more 71 (46.7)
Treatment experience
Diagnosed with AF for Z5 y 95 (62.5)
Treated by cardiologist 105 (69.1)
Medication
Aspirin 25 (16.4)
Antiarrhythmic medication 76 (50.3)
Anticoagulant 103 (67.8)
Heart-valve replacement surgery 10 (6.6)
Surgery to remove a clot 5 (3.3)
Experience with comorbidities
Hypertension 76 (50.0)
Cancer 17 (11.2)
Diabetes 28 (18.5)
Heart failure 34 (22.4)
Experience with survey events
Minor stroke or TIA 24 (15.9)
Major stroke 6 (4.0)
Blood clot in the leg 3 (2.0)
Heart attack 36 (24.0)
Moderate bleeding not caused by injury 22 (14.6)
Major bleeding 3 (2.0)
CHADS2 score* 1.4 (1.2)
Note. Percentages exclude missing values. Values represent n (%) except
AF, atrial ﬁbrillation; TIA, transient ischemic attack.
* CHADS2 score of 0 indicates low stroke risk, 1 indicates moderate stroComparing Patient and Physician Preferences
We compared the preferences of patients and physicians in
the United States and Japan by looking at two measures of
difference between the two groups. First, we measured the
difference in the relative importance of treatment-induced
events by calculating the ratio of patients’ and physicians’
relative importance for each event. We refer to this compar-
ison as an importance ratio, with 1 representing agreement
between patients and physicians. When patients place greater
relative importance than do physicians on an event, the
importance ratio is greater than 1. If physicians place greater
importance than do patients on an event, the importance ratio
is less than 1. Because the ratio for each event was estimated
using the parameters from RPL models, each ratio has its own
expected variance, stemming from the variance of the RPL
estimates that make up the ratio, and established from all the
choices collected from patients and physicians who com-
pleted the survey. With this information on the variance of
each importance ratio, we used a Wald test to jointly test
whether the importance ratio across patients and physicians
differed signiﬁcantly from 1 [20].
Second, we qualitatively compared risk tolerance between
patients and physicians in each country. We calculated the
maximum risk of major extracranial bleeding and nonmajor
clinically relevant bleeding that patients and physicians would
tolerate in exchange for reductions in the risk of nondisabling
and disabling strokes. These maximum acceptable risk (MAR)
estimates for reducing the risk of nondisabling and disabling
strokes were calculated by determining the increase in each2) United States (N ¼ 186) P-value
65.6  10.68 0.037
78 (42.6) o0.001
69 (37.1) 0.074
108 (58.1) 0.408
154 (83.7) 0.002
113 (60.8) o0.001
125 (67.2) 0.002
111 (60.0) 0.141
11 (5.9) 0.801
10 (5.4) 0.354
129 (69.7) o0.001
26 (14.1) 0.432
48 (25.9) 0.107
49 (26.3) 0.398
31 (16.7) 0.849
6 (3.2) 0.711
17 (9.2) 0.005
51 (27.6) 0.459
34 (18.3) 0.363
14 (7.7) 0.017
1.9 (1.4) 0.279
otherwise indicated.
ke risk, 2 or higher indicates moderate-to-high stroke risk [21,22].
Table 4 – Sample characteristics: Physicians.
Characteristic Japan (N ¼ 164) United States (N ¼ 107) P-value
Medical training and experience
GP/internal medicine 64 (39.0) 43 (40.2) 0.848
Cardiology 58 (35.4) 64 (59.8) o0.001
Neurosurgeon/neurologist 42 (25.6) NA NA
Z10 y of experience 158 (96.3) 93 (87.7) 0.007
Institution with 4100 beds 110 (67.1) NA NA
Treat Z10 patients with AF monthly 132 (80.5) 97 (90.7) 0.030
Prescribing pattern
Recommends aspirin to o50% of the patients 137 (83.5) 71 (66.4) 0.002
Recommends antiarrhythmics to o50% of the patients 137 (83.5) 73 (68) 0.005
Recommends anticoagulants to o50% of the patients 41 (25.0) 7 (6.5) o0.001
Recommends rate control agents to o50% of the patients 132 (80.5) 34 (31.8) o0.001
Note. Percentages exclude missing values. Values represent n (%).
AF, atrial ﬁbrillation; GP, general practitioner; NA, not applicable.
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a 1-percentage-point decrease in each stroke risk. We compared
the MAR estimates between patients and physicians in each
country.Results
Sample
US patients with a self-reported diagnosis of AF were invited via
e-mail to participate in the survey. Of those who responded to the
invitation (N ¼ 390), 216 conﬁrmed that they were eligible to
complete the survey. Of the 216 eligible patients, 196 consented
to participate and 186 completed the survey. US physicians were
also invited to participate in the survey via e-mail. Out of those
invited (N ¼ 113), 111 respondents conﬁrmed that they were
eligible to participate. Out of those who were eligible, 107
completed the survey. Response rates for Japanese patients and
physicians are described elsewhere [16]. Table 3 summarizes the
characteristics of the patients in the US and Japanese samples.
Physician characteristics are presented in Table 4.
Patients in the US sample had an average reported age of 65.6
 10.68 years. Japanese patients were about 2 years younger on
average (63.3  9.05 years). Most patients in the United States and
Japan were men (57.4% in the United States and 88.2% in Japan)
and had been diagnosed with AF within the past 5 years (58.1% in
the United States and 62.5% in Japan). In Japan, most patients
took anticoagulants (67.8%) and only 16.4% of the patientsTable 5 – Relative importance estimates of nonfatal card
Outcome Relative impor
US patients US ph
All-cause death 1.00 (.) 1.
Nondisabling stroke 0.75 (0.14) 0.52
Disabling, nonfatal stroke 1.68 (0.21) 0.65
Myocardial infarction 0.47 (0.05) 0.28
Non-CNS, systemic embolism 0.58 (0.09) 0.19
Nonmajor clinically relevant bleeding 0.29 (0.04) 0.09
Extracranial major bleeding 0.92 (0.15) 0.43
CNS, central nervous system; SE, standard error.
* Apart from all-cause death, all events presented in this table are nonfa
† Relative importance is equivalent to preventing deaths per 10,000 patireported taking aspirin daily to treat AF. CHADS2 is a clinical
prediction algorithm used to evaluate stroke risk in patients with
AF. A score of 0 indicates low stroke risk, a score of 1 indicates
moderate stroke risk, and a score of 2 or more indicates
moderate-to-high stroke risk [21,22]. The average CHADS2 score
among US patients in this study was 1.9  1.4, whereas among
Japanese patients it was 1.4  1.2.
Most physicians had been practicing medicine for at least 10
years (87.7% in the United States and 96.3% in Japan). In the
United States, the distribution of physicians by specialty was
59.8% cardiologists and 40.2% primary care physicians or intern-
ists. In Japan, most physicians were general practitioners or
internists (39%), followed by cardiologists (35.4%). Neurologists
and neurosurgeons made up 25.6% of the physician sample in
Japan. Most US physicians reported recommending daily aspirin
therapy for less than 50% of their patients with AF (66.4%) and
anticoagulants to at least 50% of their patients with AF (93.5%).
Differences in Preferences between the United States and
Japan
A summary of the relative importance of the events for patients
and physicians in both the United States and Japan is presented
in Table 5. For US patients, disabling stroke was the event with
the highest relative importance (1.68), followed by all-cause death
(1.0) and extracranial major bleeding (0.92). The event with the
lowest relative importance among US patients was nonmajor
clinically relevant bleeding (0.29). In contrast, among Japanese
patients the highest relative importance was for all-cause deathiovascular events.*
tance (SE) of change from 0% to 1% risk of event.†
ysicians Japanese patients Japanese physicians
00 (.) 1.00 (.) 1.00 (.)
(0.06) 0.32 (0.15) 0.13 (0.15)
(0.07) 0.62 (0.26) 0.16 (0.08)
(0.03) 0.13 (0.05) 0.04 (0.05)
(0.03) 0.14 (0.09) 0.05 (0.05)
(0.02) 0.04 (0.07) 0.06 (0.02)
(0.04) 0.24 (0.10) 0.16 (0.06)
tal events.
ent-years.
Table 6 – Importance ratios for cardiovascular
events (patients relative to physicians).
Outcome* US
importance
ratio (SE)
Japan
importance
ratio (SE)
All-cause death 1.00 1.00
Nondisabling stroke 1.69 (0.60) 2.36 (0.68)
Disabling stroke 2.76 (1.58) 3.89 (0.21)
Non-CNS, systemic
embolism
3.69 (2.12) 2.64 (0.82)
Myocardial infarction 1.98 (1.03) 3.67 (11.37)
Nonmajor clinically
relevant bleeding
3.91 (2.90) 0.52 (0.37)
Extracranial major
bleeding
2.93 (1.95) 1.52 (0.13)
Wald test P-value 0.90 0.001
CNS, central nervous system; SE, standard error.
* Apart from all-cause death, all events presented in this table are
nonfatal events.
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(0.32). Events with the lowest relative importance in Japan were
nonmajor clinically relevant bleeding (0.04), nonfatal myocardial
infarction (0.13), and nonfatal systemic embolism (0.14).
Among US physicians, the highest relative importance was for
all-cause death (1.0), followed by disabling stroke (0.65) and
nondisabling stroke (0.52). Japanese physicians also considered
all-cause death to have the highest relative importance (1.0), but
they considered disabling stroke and extracranial major bleeding
to be of equal relative importance (0.16).
Patient and Physician Comparisons
Table 6 summarizes the importance ratios for patients and physi-
cians in both the United States and Japan. With one exception, theFig. 2 – Maximum acceptable risk (MAR) of bleeding events—US
conﬁdence intervals.importance ratios were greater than 1, indicating that patients
placed a higher level of relative importance on each nonfatal risk
relative to death than did physicians. In Japan, patients placed a
lower level of relative importance on nonmajor clinically relevant
bleeding than did physicians. The largest importance ratio in the
United States was for nonmajor clinically relevant bleeding (3.91;
P ¼ 0.09), indicating that the relative importance of nonmajor
clinically relevant bleeding (compared with all-cause death) was
almost 4 times larger for patients than for physicians (although the
difference did not reach formal statistical signiﬁcance). In Japan, the
largest importance ratio was for disabling stroke (3.89; P o 0.01),
indicating that disabling stroke was nearly 4 times as important to
Japanese patients as it was to their physicians. The result of the joint
test of signiﬁcance of the importance ratios was P ¼ 0.90 in the US
sample. This result suggests that despite ﬁnding some qualitative
differences in the preferences of patients and physicians in the US
survey, we do not have information to reject that the relationship of
preferences across events is different among patients and physi-
cians. The result of the joint test of signiﬁcance in the Japanese
sample was P o 0.001, suggesting that patient preferences differed
systematically from physician preferences among Japanese
respondents.
Fig. 2 shows the MAR estimates for extracranial major bleed-
ing and nonmajor clinically relevant bleeding associated with a
1-percentage-point reduction in the risk of nondisabling stroke
and a 1-percentage-point reduction in the risk of disabling stroke
for US patients and physicians. Physicians were willing to accept
a treatment-related risk of extracranial major bleeding of up to
1.3% or a treatment-related risk of nonmajor clinically relevant
bleeding of up to 5.3% to reduce the risk of nondisabling stroke by
1-percentage-point. Patients were willing to accept similar levels
of risks in exchange for a 1-percentage-point reduction in the risk
of nondisabling stroke when compared with physicians.
For US physicians, the MAR estimates for bleeding events
corresponding to reductions in the risks of disabling strokes and
nondisabling strokes were not statistically different. In contrast,
patients were willing to accept up to a 6.3% treatment-related riskpatients and physicians. Vertical lines around MARs are 95%
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reduction in the risk of disabling stroke, compared with only a
2.7% treatment-related risk of nonmajor clinically relevant bleed-
ing for a 1-percentage-point reduction in the risk of nondisabling
stroke. For both patients and physicians, risk tolerance was
statistically signiﬁcantly higher for nonmajor clinically relevant
bleeding than for extracranial major bleeding.
Fig. 3 shows the MAR estimates for Japan. Physicians were willing
to accept a treatment-related risk of extracranial major bleeding of
up to 0.8% or a risk of nonmajor clinically relevant bleeding of up to
2.2% in exchange for a 1-percentage-point reduction in the risk of
nondisabling stroke. These MAR estimates were approximately the
same as those for a 1-percentage-point reduction in the risk of
disabling stroke. As in the United States, patients in Japan seem to
have made a greater distinction between nondisabling stroke and
disabling strokes and are willing to accept higher levels of bleeding
risks to avoid the risk of disabling strokes than do physicians.
Patients were willing to accept a treatment-related risk of nonmajor
clinically relevant bleeding of up to 10.5% to reduce the risk of
disabling stroke by 1-percentage-point, which is 4 times as high as
the level of bleeding risk that physicians were willing to accept.Conclusions
By quantifying treatment preferences, we found that the relative
importance of events associated with the use of anticoagulants
differs between patients with AF and physicians in both the
United States and Japan. In almost all cases, patients assigned
greater relative importance to events than did physicians. Only
nonmajor clinically relevant bleeding was more important to
physicians than to patients in Japan, even though this end point
was among the least important for patients and physicians.
The risk-tolerance estimates for patients and physicians
revealed both similarities and differences in treatment perspectives
between the United States and Japan. First, physicians in both
countries made little distinction between the risks of nondisablingFig. 3 –Maximum acceptable risk (MAR) of bleeding events—Japa
95% conﬁdence intervals.and disabling stroke. In addition, the level of risk tolerance of
extracranial major bleeding events and nonmajor clinically relevant
bleeds was not statistically different for physicians in these coun-
tries. This consistency in risk tolerance was not observed between
patients with AF in the United States and Japan.
US physicians were, on average, more risk tolerant than Japa-
nese physicians. Japanese patients were, however, on average,
more risk tolerant than US patients. This was particularly evident
in the estimates of patients’ tolerance of treatment-related bleeding
risks borne in exchange for avoiding nondisabling strokes. Although
US patients had MARs of extracranial major bleeding and nonmajor
clinically relevant bleeding of 0.8% and 2.7%, respectively, to reduce
the risk of nondisabling stroke, MARs of the same bleeding events
were at least 60% greater for Japanese patients—1.3% and 6.6%,
respectively. In addition, we found that US patients were less risk
tolerant than US physicians particularly when it came to reducing
the risk of nondisabling strokes.
Overall, preferences of patients with AF and physicians were
statistically different in Japan, suggesting potential disagreement
about the appropriate therapeutic level of anticoagulation. In the
United States, however, preferences of patients and physicians
were not statistically different when all estimates were tested
jointly, suggesting that perhaps recent strategies for anticoagu-
lation services and self-monitoring have helped reduce disagree-
ment between patients and physicians because these strategies
increase patients’ understanding of dosing and their ability to
inﬂuence their level of anticoagulation [23]. Although our study
was not designed to evaluate the impact of speciﬁc macro-
economic or societal factors on preferences, we acknowledge
that it is possible that social differences and differences in health
systems between the two countries could have inﬂuenced the
observed patterns of preferences among patients and physicians.
Societal values in the United States and the west in general tend
to be individualistic, whereas in Japan they are more collectiv-
istic. This difference could imply that patients in the United
States expect less support after experiencing severely debilitating
events and expect greater limitations as a consequence of thesenese patients and physicians. Vertical lines around MARs are
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and imposes strict control over medical fees, which help limit the
ﬁnancial consequences of debilitating events, particularly if these
events carry long-term sequelae. At the time the survey was
administered in the United States, no expanded health insurance
coverage associated with the Patient Protection and Affordable
Care Act was yet in place, and it is possible that patients
considered future ﬁnancial implications of the events in the
study as they completed the choice questions.
Recently, novel oral anticoagulants (NOACs) such as dabiga-
tran, rivaroxaban, and apixaban have become available. All
NOACs have been shown to be superior to or noninferior to
warfarin in preventing stroke and systemic thromboembolism,
whereas they consistently showed signiﬁcantly less incidence of
intracranial and extracranial hemorrhages than did warfarin
(references of Randomized Evaluation of Long-term Anticoagu-
lant Therapy (RE-LY), Rivaroxaban Once Daily Oral Direct Factor
Xa Inhibition Compared with Vitamin K Antagonism for Preven-
tion of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET
AF), and Apixaban for Reduction in Stroke and Other Throm-
boembolic Events in Atrial Fibrillation (ARISTOTLE) studies).
Especially, the incidence of hemorrhagic stroke was markedly
less in patients treated with NOACs than in those treated with
warfarin. These aspects of new anticoagulants would affect the
choices of both patients and physicians.
Limitations
An important limitation of studies such as this, which rely on
stated choices as opposed to actual choices, is that people are not
required to experience the trade-offs they are asked to make in
the choice questions. We tried to minimize any potential bias
from the hypothetical nature of the questions by presenting a
choice setting and treatment alternatives that mimic real-world
treatment-decision contexts as closely as possible.
Second, preference estimates inferred through treatment
choices are inﬂuenced by patients’ and physicians’ interpretation
of the event deﬁnitions in the survey, including all-cause death,
which we used to normalize the importance weights for respond-
ents in different samples. We attempted to mitigate problems of
misinterpretation of the events by consulting with clinical
experts in the ﬁeld of AF and conducting in-person interviews
with patients with AF and physicians.
Third, there are no formal power calculations for testing
differences in preferences using discrete-choice experiments.
Although an experimental design was used to optimize the
preference information obtained from choice questions, statisti-
cal signiﬁcance is partly determined by nonstatistical factors
such as measurement and preference heterogeneity. For this
reason, lack of statistical signiﬁcance in the differences of
preferences among US patients and physicians should be inter-
preted with caution because it is possible that larger sample sizes
could have yielded signiﬁcant differences.
Finally, no action was taken to ensure the representativeness
of any of the samples on a national level, potentially limiting the
generalizability of the survey results.
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